title: Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy.
abstract: OBJECTIVE
  To evaluate long-term outcome and biochemical progression-free survival (bPFS) in high-risk prostate cancer patients treated with brachytherapy combined with external-beam radiation therapy (EBRT) and androgen deprivation therapy (ADT).
  
  
  METHODS
  We retrospectively analyzed 97 high-risk prostate cancer patients treated with brachytherapy combined with EBRT and ADT. During follow-up, the post-operation prostate-specific antigen (PSA) level was monitored regularly and biochemical relapse, progression to castration-resistant prostate cancer or metastases, and causes of death were documented. We evaluated bPFS, cause-specific survival (CSS) and overall survival (OS).
  
  
  RESULTS
  The bPFS, CSS and OS of the patients were 81.4%, 88.7% and 81.4%, respectively. The bPFS of the subcategories of patients stratified based on the presence or absence of a Gleason pattern 5 were 55.6% and 87.7%, respectively.
  
  
  CONCLUSIONS
  Brachytherapy combined with EBRT and ADT can effectively control PSA level and delay biochemical relapse in localized high-risk prostate cancer. However, patients presenting with a Gleason pattern 5 should be managed with further treatment intensification.
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Wei-gang
authors.initials: WG
authors.lastname: Yan
authors.forename: Han-zhong
authors.initials: HZ
authors.lastname: Li
authors.forename: Zhi-gang
authors.initials: ZG
authors.lastname: Ji
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Zhi-en
authors.initials: ZE
authors.lastname: Zhou
authors.forename: Zhi-peng
authors.initials: ZP
authors.lastname: Mai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001918:Brachytherapy; D059248:Chemoradiotherapy; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists